The FDA’s move to lift the hold on Zentalis Pharmaceuticals’ sole clinical-stage drug may have been good news for the biotech—but it’s been bad news for some of its staff. The company is now laying off 40% of its employees as it gears up for registrational studies in ovarian cancer.

Two weeks after its bacteria-based therapy scored a phase 2 lung cancer win, OS Therapies has penned a deal that will secure the full intellectual property rights to the drug along with a pair of additional clinical-stage therapies.

Decentralized clinical trials, which allow patients to participate locally or remotely using digital tech, end up enrolling more diverse populations than traditional trials, according to new data from the Tufts Center for the Study of Drug Development’s PACT consortium.

Demand slipped for several large contract research organizations last year, and a new report from William Blair suggests these firms shouldn’t expect much improvement in 2025.

Though the administration said Tuesday that Medicaid would not be caught up in a hold on federal program payments, industry groups and legislators say that portals in all 50 states are down. This comes as other questions remain on whether Monday's ambiguous memo will interrupt clinical research, community health centers, suicide prevention, state infectious disease surveillance and other government-backed efforts.

So far this month, companies in the biopharma industry have raised prices on more than 930 products but the increases have largely been modest, averaging 4%.

A Tuesday night order pulls federal funds from healthcare providers treating trans those under 19 with what the Trump administration refers to as "chemical and surgical mutilation." The order also pulls coverage of the services from government insurers and signals broad law enforcement support for prohibitory state laws.